The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension

Front Endocrinol (Lausanne). 2022 Dec 9:13:1097968. doi: 10.3389/fendo.2022.1097968. eCollection 2022.
No abstract available

Keywords: BrigHTN; CIN-107; aldosterone; baxdrostat; blood pressure; clinical trial; hypertension; resistant hypertension.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aldosterone*
  • Blood Pressure
  • Cytochrome P-450 CYP11B2
  • Enzyme Inhibitors
  • Humans
  • Hypertension*
  • Mineralocorticoid Receptor Antagonists

Substances

  • Aldosterone
  • Cytochrome P-450 CYP11B2
  • Mineralocorticoid Receptor Antagonists
  • Enzyme Inhibitors